Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).
The review found no eligible studies for this question.
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).